Finasteride for Women: Evidence, Risks, and Who May Benefit

Finasteride is not FDA-approved for use in women. It is approved only for men with androgenetic alopecia (AGA) and men with benign prostatic hyperplasia. However, dermatologists in the US and internationally do prescribe finasteride off-label for postmenopausal women with female pattern hair loss (FPHL, also called female androgenetic alopecia) when other treatments have been inadequate. This page presents the evidence, the limitations, and the critical safety information.

What Is Female Pattern Hair Loss (FPHL)?

Female pattern hair loss is the most common form of hair loss in women, affecting approximately 50% of women by age 50 and up to 75% of women by age 65 (Blume-Peytavi et al., 2011). Unlike male AGA, which typically progresses to a specific baldness pattern (Norwood-Hamilton scale), FPHL presents as diffuse thinning of the crown and mid-scalp, typically with preservation of the frontal hairline (Ludwig scale I-III).

The role of androgens (DHT) in FPHL is less clear than in male AGA. Many women with FPHL have normal androgen levels; their follicles appear to have heightened sensitivity to normal circulating androgens. Some women with FPHL, however, particularly those with signs of hyperandrogenism (acne, hirsutism, irregular periods, polycystic ovary syndrome), do have elevated androgens.

FDA-Approved Treatments for FPHL

The only FDA-approved treatments for FPHL are:

• Topical minoxidil 2% (OTC, approved for women), the standard first-line treatment
• Topical minoxidil 5% (OTC; the 5% foam has been FDA-approved for women since 2014)

All other treatments for FPHL, including finasteride, spironolactone, and oral minoxidil, are off-label.

Evidence for Finasteride in Women with FPHL

The evidence base for finasteride in women is considerably smaller and more mixed than for men. Key trials:

Study	Population	Dose	Outcome
Price et al., 2000 (negative)	Postmenopausal women, n=137, 12 months	1 mg/day	No significant improvement vs. placebo
Trüeb et al., 2004 (positive)	Postmenopausal women, n=12, 12 months	2.5 mg/day	Moderate improvement in hair density; small sample
Iorizzo et al., 2006 (positive)	Premenopausal women with FPHL taking an oral contraceptive, n=37, 12 months	2.5 mg/day	Significant improvement in hair density vs. baseline; no control group
Yeon et al., 2011 (positive, uncontrolled)	Normoandrogenic women with FPHL, n=87, 12 months	5 mg/day	Hair density and thickness increased; no placebo group

Summary of the evidence:

• Finasteride 1 mg/day does not appear to benefit postmenopausal women with normal androgen levels based on the two largest RCTs
• Higher doses (2.5-5 mg/day) may provide benefit in postmenopausal women; smaller studies show positive results but lack strong RCT data
• Women with hyperandrogenism (elevated androgens) may be more likely to respond to finasteride at any dose
• No large, well-powered RCT has demonstrated benefit at 1 mg/day in women overall

Who Might Be Considered for Finasteride (Physician Discussion)?

• Postmenopausal women (pregnancy risk eliminated; no absolute hormonal contraindication)
• Women with elevated androgens (confirmed on lab testing) and FPHL unresponsive to minoxidil
• Women using effective non-hormonal contraception who understand and accept the absolute contraindication in pregnancy

Finasteride should never be prescribed to premenopausal women who are or may become pregnant. Women of childbearing potential who are candidates for anti-androgen therapy for FPHL more commonly receive spironolactone (50-200 mg/day), which has a better-characterized safety profile in premenopausal women and broader use in FPHL clinical practice.

Finasteride vs. Spironolactone for Women

	Finasteride (off-label)	Spironolactone (off-label)
Mechanism	5-alpha-reductase inhibitor (reduces DHT)	Androgen receptor antagonist + anti-mineralocorticoid
FDA status for FPHL	Not approved	Not approved
Pregnancy safety	Category X, absolute CI	Category C/D, not recommended in pregnancy
Use in premenopausal women	Very limited; contraindicated without reliable non-hormonal contraception	More commonly used with adequate contraception
Evidence in FPHL	Mixed (positive at 2.5 mg+; negative at 1 mg/day in major RCTs)	Positive observational data; no large FPHL-specific RCTs
Common side effects	Menstrual changes possible; sexual effects (data limited in women)	Menstrual irregularity, breast tenderness, hyperkalemia (high doses)

Frequently Asked Questions

Can women take finasteride for hair loss?

Off-label, and with major restrictions. Finasteride is not FDA-approved for women. Postmenopausal women, and in some cases premenopausal women using non-hormonal contraception, may be prescribed finasteride off-label by a dermatologist. The evidence suggests that higher doses (2.5 mg+) and women with elevated androgen levels are most likely to respond. Women who are or may become pregnant must never take finasteride under any circumstances.

What dose of finasteride is used for women’s hair loss?

The 1 mg/day dose used in men has not shown significant benefit in two major RCTs in women. Dermatologists who prescribe finasteride off-label for postmenopausal women or women with hyperandrogenism typically use 2.5 mg/day, with some using up to 5 mg/day. The optimal dose has not been established by large RCTs in women.

Why can’t women of childbearing age take finasteride?

Finasteride is a Pregnancy Category X drug because it causes abnormalities of the external genitalia of male fetuses. DHT produced by 5-alpha-reductase Type II is required for normal male genital development in utero. Blocking it with finasteride during pregnancy causes hypospadias (abnormal urethral opening) and ambiguous genitalia in male offspring. Even topical handling of crushed or broken finasteride tablets poses a risk to pregnant women from dermal absorption. This is why the FDA requires a special Medication Guide and warns that intact tablets should not be handled by women who are pregnant.

Sources

• Price VH, et al. “Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.” J Am Acad Dermatol. 2000;43(5 Pt 1):768-776.
• Iorizzo M, et al. “Finasteride treatment of female pattern hair loss.” Arch Dermatol. 2006;142(3):298-302.
• Yeon JH, et al. “5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss.” J Eur Acad Dermatol Venereol. 2011;25(2):211-4.
• Merck & Co. Propecia (finasteride 1 mg) US Prescribing Information. Revised 2022. [Pregnancy Category X classification]